This paper has been presented at the 2nd International Conference of the Journal of Travel Medicine and Infectious Disease, 12th September 12, 2007, as a poster.
Vaccination Strategies Against Hepatitis A in Travelers Older Than 40 Years: An Economic Evaluation
Article first published online: 24 JUL 2009
© 2009 International Society of Travel Medicine
Journal of Travel Medicine
Volume 16, Issue 5, pages 344–348, September/October 2009
How to Cite
Costas, L., Vilella, A., Trilla, A., Serrano, B., Vera, I., Roldán, M., Sancho, M.-P., Bayas, J.-M., Gascón, J. and Costa, J. (2009), Vaccination Strategies Against Hepatitis A in Travelers Older Than 40 Years: An Economic Evaluation. Journal of Travel Medicine, 16: 344–348. doi: 10.1111/j.1708-8305.2009.00320.x
- Issue published online: 24 SEP 2009
- Article first published online: 24 JUL 2009
Background In recent years, the number of travelers aged >40 years who acquire hepatitis A while traveling has increased. Therefore, there is a need to review hepatitis A vaccination protocols in travelers. The aims of the study were to assess immunity levels to hepatitis A virus (HAV) in international travelers >40 years and to determine the least costly immunization strategy.
Methods A serological examination of HAV antibodies in 427 international travelers aged >40 years traveling endemic zones was carried out. The prevalence of antibodies in each age group was assessed. The costs of two preventive strategies, direct vaccination of all subjects (independent of the immune status) or screening and subsequent vaccination of susceptible subjects were compared. The critical value of prevalence (CVP) (the value at which the costs for the two strategies are equal) was calculated.
Results Total prevalence of HAV antibodies was 78.9% [95% confidence interval (CI): 74.8–82.5] and was 80.0% (95% CI: 73.8–85.2) in men and 77.9% (95% CI: 71.9–83.2) in women. There was a positive association with age. In the 40 to 49, 50 to 59, 60 to 69, and 70 to 95 years age groups, the prevalence rates were 62.6 (95% CI: 53.8–71.5), 76.8 (95% CI: 70.0–82.7), 91.7 (95% CI: 85.2–95.6), and 97.5% (95% CI: 87.4–99.6), respectively. The CVP was 58.4% using two doses of vaccine.
Conclusions The CVP was lower than the prevalence rate found in our international travelers. Therefore, we recommend systematic screening for HAV antibodies before selective vaccination of international travelers aged >40 years traveling to hepatitis A endemic zones.